A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 52
• 4 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild to moderate atopic dermatitis (a long-lasting itchy skin condition). It tests TIR-C 2% cutaneous emulsion against a placebo.

Age

18 years or older

Sex

Women and men can join.

Disease stage

Mild to moderate atopic dermatitis

Main reasons for not taking part

• Healthy volunteers cannot join.

Read by machine on 9 Nov 2026.

Sites (4)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details